00:00What is Myasthenia Grave?
00:04Myasthenia Grave is a chronic autoimmune disease
00:08that affects the neuromuscular junction,
00:10altering the transmission of the impulse between the nerve and the muscle,
00:14and it is a rare disease, not very rare.
00:17It is estimated that about 17,000 people in Italy are affected by Myasthenia Grave,
00:23and it is a disease characterized by muscle fatigue,
00:28that is, the symptoms worsen with effort and improve with rest.
00:32It is a disease that can involve several muscle districts,
00:38it is a heterogeneous disease, it can involve the extraocular muscles,
00:42giving rise to diplopia, double vision, palpebral ptosis,
00:46the muscles that are important for phonation and chewing,
00:49therefore giving difficulty in speaking, chewing, but also in swallowing,
00:53and it can also give fatigue to the arteries.
00:56The most severe event is when the muscles are involved in the respiratory tract,
01:03in this case the patient can go into respiratory failure
01:06and may require mechanical ventilation support and intensive care.
01:10From a therapeutic point of view, Myasthenia Grave is a disease
01:14that responds quite well to traditional therapy.
01:18However, there are about 10-15% of patients who do not respond to traditional therapies,
01:25which are inhibitors of acetylcholinesterase, corticosteroids,
01:31immunosuppressors such as azathioprine or mycophenolate.
01:35Moreover, there are several patients who suffer from side effects
01:40of the therapy with chronic corticosteroids.
01:43These patients can benefit from innovative therapies,
01:47among these, for example, Lefkartijimod,
01:49which is a fragment of an antibody that promotes the degradation of IgG pathogens,
01:55reducing the level of antibodies that cause the disease,
01:58such as the antibody specific to the receptor of acetylcholinesterase,
02:01thus improving the symptoms and reducing the disability associated with this pathology.